Form 4: RA Capital Sells Vor Biopharma Shares

RA Capital Management, L.P. and its affiliates have reported the sale of a significant number of Vor Biopharma Inc. common shares across multiple transactions.

Summary

• RA Capital Management, L.P., along with affiliated entities RA Capital Healthcare Fund, L.P., Peter Kolchinsky, and Rajeev Shah, have disclosed transactions involving Vor Biopharma Inc. (VOR).
• These transactions, occurring between April 8, 2026, and April 10, 2026, involved the sale of common stock.
• The sales were executed at weighted average prices ranging from $15.75 to $16.91 per share.
• Following these sales, RA Capital Management, L.P. and its affiliates continue to beneficially own a substantial number of Vor Biopharma shares.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative sentiment due to significant share sales by a major holder, although the exact reasons for the sales are not detailed.

Negatives

• RA Capital Management, L.P. and its affiliates sold a total of 609,233 shares of Vor Biopharma common stock.
• The sales occurred over a period of four days, indicating a consistent divestment.

Future Outlook

No forward-looking statements or guidance were provided in this filing.

Management Comments

• The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Industry Context

StockSavvy.ai notes that Form 4 filings are crucial for tracking insider transactions. Significant sales by large holders like RA Capital Management can sometimes signal a change in sentiment or strategy, though the reasons can vary widely and may not always reflect negatively on the company's long-term prospects.

Stakeholder Impact

• Shareholders may view the significant sales by RA Capital Management as a potential indicator of reduced confidence or a need for liquidity, which could influence market perception and stock price.

Key Dates

Recommendation

While the significant sales by a major holder warrant attention, this Form 4 filing solely reports transactions and does not provide operational or financial performance data. Without further context on the company's performance or the rationale behind RA Capital's sales, a 'hold' recommendation is prudent, suggesting investors monitor future filings and company announcements.

Keywords

Vor Biopharma, VOR, RA Capital Management, Form 4, Insider Trading, Stock Sale, Beneficial Ownership